Takeda and Ovid Strike Partnership to Develop Investigational Agent for Rare Pediatric Epilepsy

Thursday, January 19, 2017 | Epilepsy & Seizure Disorders , Personnel/Company News , Product Launches and Updates


Takeda and Ovid Therapeutics are teaming up for the clinical development and commercialization of Takeda’s investigational new drug TAK-935, a novel CH24H inhibitor, in rare pediatric epilepsies. TAK-935 has successfully completed Phase 1 clinical development and will be moving into Phase 1b/2a clinical studies in rare epileptic encephalopathies where patients continue to suffer from significant unmet medical needs.

Under the terms of the agreement, Takeda received equity in Ovid and may be eligible to receive certain milestone payments based on the advancement of TAK-935. The companies will share in the development and commercialization costs on a 50/50 basis and, if successful, the companies will share in the profits on a 50/50 basis. Takeda will lead commercialization in Japan, and has the option to lead in Asia and other selected geographies. Ovid will lead clinical development activities and commercialization of TAK-935 in the US, Europe, Canada, and Israel.

All activities of the collaboration regarding TAK-935 will be guided by the Takeda/Ovid “One Team” concept, an integrated and interdisciplinary team from both companies devoted to the successful advancement of TAK-935 across rare epilepsy syndromes. The companies expect to initiate a Phase 1b/2a study in 2017 in patients with rare epileptic encephalopathies including Dravet syndrome, Lennox-Gastaut syndrome, and Tuberous Sclerosis Complex. 

Next Story

Comments

You must be logged in to leave a comment.